PL EN


Preferences help
enabled [disable] Abstract
Number of results
2010 | 57 | 4 | 561-566
Article title

Serum metallothionein in newly diagnosed patients with childhood solid tumours

Content
Title variants
Languages of publication
EN
Abstracts
EN
Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease. Time-consuming imaging methods, examination of cerebrospinal fluid or tumour tissue and assays for hormones and tumour markers have been used for cancer diagnosis. However, no specific marker for diagnosis of childhood solid tumours has been discovered yet. In this study, metallothionein (MT) was evaluated as a prospective marker for such diseases. Serum metallothionein levels of patients with childhood solid tumours were determined using differential pulse voltammetry - Brdicka reaction. A more than 5-fold increase in the amount of metallothionein was found in sera of patients suffering from cancer disease, compared with those in sera of healthy donors. The average metallothionein level in the sera of healthy volunteers was 0.5 ± 0.2 μmol · dm-3 and was significantly different (p<0.05, determined using the Schefe test) from the average MT level found in serum samples of patients suffering from childhood solid tumours (3.4 ± 0.8 μmol · dm-3). Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours.
Keywords
Publisher

Year
Volume
57
Issue
4
Pages
561-566
Physical description
Dates
published
2010
received
2010-06-19
revised
2010-08-31
accepted
2010-11-03
(unknown)
2010-11-09
Contributors
author
  • Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno, Czech Republic
  • Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
author
  • Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno, Czech Republic
author
  • Faculty of Biomedical Engineering, Department of Biomedical Technology, Czech Technical University in Prague, Prague, Czech Republic
  • Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and Faculty Hospital Motol, Charles University, Prague, Czech Republic
author
  • Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno, Czech Republic
author
  • Department of Clinical Biochemistry and Pathobiochemistry, 2nd Faculty of Medicine and Faculty Hospital Motol, Charles University, Prague, Czech Republic
  • Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and Faculty Hospital Motol, Charles University, Prague, Czech Republic
  • Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
author
  • Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno, Czech Republic
References
  • Adam V, Baloun J, Fabrik I, Trnkova L, Kizek R (2008a) An electrochemical detection of metallothioneins at the zeptomole level in nanolitre volumes. Sensors 8: 2293-2305.
  • Adam V, Blastik O, Krizkova S et al. (2008b) Application of the Brdicka reaction in determination of metallothionein in patients with tumours. Chem Listy 102: 51-58.
  • Adam V, Fabrik I, Eckschlager T et al. (2010) Vertebrate metallothioneins as target molecules for analytical techniques. Trac-Trends Anal Chem 29: 409-418.
  • Afridi HI, Kazi TG, Kazi NG, et al. (2009) Determination of Copper and Iron in Biological Samples of Viral Hepatitis (A-E) Female Patients. Biol Trace Elem Res 129: 78-87.
  • Anonymous (2008) The global burden of disease: 2004 update. World Health Organization Geneva.
  • Anonymous (2009) Novotvary 2006/Cancer incidence 2006. ÚZIS ČR NOR ČR 2009 Praha.
  • Bacolod MD, Johnson SP, Ali-Osman F et al. (2002) Mechanisms of resistance to 13-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 1: 727-736.
  • Bacolod MD, Fehdrau R, Johnson SP et al. (2009) BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 63: 753-758.
  • Brdicka R (1933) Polarographic studies with the dropping mercury kathode. -Part XXXI. A new test for proteins in the presence of cobalt salts in ammoniacal solutions of ammonium chloride. Coll Czech Chem Commun 5: 112-128.
  • Brdicka R (1937a) Application of the polarographic effect of proteins in cancer diagnosis. Nature 139: 330-330.
  • Brdicka R (1937b) Polarographic investigation in serological cancer diagnosis. Nature 139: 1020-1021.
  • Brdicka R (1938) Zur frage nach der natur der polarographisch feststellbaren serumverandrungen bei Krebs. Klinische Wochenschrift 18: 305-308.
  • Churackova M. (2008) Nádory centrálního nervového systému u dětí a mladistvých. Onkologie 2: 234-238.
  • Eckschlager T, Adam V, Hrabeta J, Figova K, Kizek R. (2009) Metallothioneins and Cancer. Curr Protein Pept Sci 10: 360-375.
  • Fabrik I, Krizkova S, Huska D et al. (2008a) Employment of electrochemical techniques for metallothionein determination in tumor cell lines and patients with a tumor disease. Electroanalysis 20: 1521-1532.
  • Fabrik I, Ruferova Z, Hilscherova K et al. (2008b) A determination of metallothionein in larvae of freshwater midges (Chironomus riparius) using Brdicka reaction. Sensors 8: 4081-4094.
  • Franklin RB, Costello LC (2007) Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 463: 211-217.
  • Heyrovsky J (1938) Polarographic research on cancer. Nature 142: 317-319.
  • Heyrovsky M (2005) Rudolf Brdička a fyzikální chemie. Od polarografie po hmotnostní spektrometrii. Vesmír 84: 257-259.
  • Jin RX, Huang JX, Tan PH, Bay BH (2004) Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 10: 74-79.
  • Jogi A, Vallon-Christersson J, Holmquist L et al. (2004) Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth survival and aggressive behavior. Exp Cell Res 295: 469-487.
  • Kalous V (2004) 70 let od objevu Brdičkovy polarografické reakce bílkovin. Klin Biochem Metab 12: 265-267.
  • Kimura T, Itoh N (2008) Function of metallothionein in gene expression and signal transduction: Newly found protective role of metallothionein. J Health Sci 54: 251-260.
  • Kizek R, Trnkova L, Palecek E (2001) Determination of metallothionein at the femtomole level by constant current stripping chronopotentiometry. Anal Chem 73: 4801-4807.
  • Knipp M (2009) Metallothioneins and Platinum(II) Anti-Tumor Compounds. Curr Med Chem 16: 522-537.
  • Krizkova S, Fabrik I, Adam V et al. (2008) Utilizing of adsorptive transfer stripping technique Brdicka reaction for determination of metallothioneins level in melanoma cells blood serum and tissues. Sensors 8: 3106-3122.
  • Krizkova S, Adam V, Eckschlager T, Kizek R (2009a) Using of chicken antibodies for metallothionein detection in human blood serum and cadmium-treated tumour cell lines after dot- and electroblotting. Electrophoresis 30: 3726-3735.
  • Krizkova S, Blahova P, Nakielna J et al. (2009b) Comparison of Metallothionein Detection by Using Brdicka Reaction and Enzyme-Linked Immunosorbent Assay Employing Chicken Yolk Antibodies. Electroanalysis 21: 2575-2583.
  • Krizkova S, Fabrik I, Adam V et al. (2009c) Metallothionein - a promising tool for cancer diagnostics. Bratisl Med J 110: 93-97.
  • Laemmli UK (1970) Cleavage of Structural Proteins During Assembly of Head of Bacteriophage-T4. Nature 227: 680-685.
  • Lara-Bohorquez C, Gonzalez-Campora R, Mendoza-Garcia E e.t al (2008) TP53 BCL-2. p21(Waf1/Cip1) and metallothionein as markers of differentiation response to treatment and prognosis in neuroblastic tumors. Anal Quant Cytol Histol 30: 105-112.
  • Li Y, Maret W (2008) Human metallothionein metallomics. J Anal At Spectrom 23: 1055-1062.
  • Masters BA, Quaife CJ, Erickson JC et al. (1994) Metallothionein-III Is Expressed in Neurons That Sequester Zinc in Synaptic Vesicles. J Neurosci 14: 5844-5857.
  • McGee HM, Woods GM, Bennett B, Chung RS (2010) The two faces of metallothionein in carcinogenesis: photoprotection against UVR-induced cancer and promotion of tumour survival. Photochem Photobiol Sci 9: 586-596.
  • Milnerowicz H, Bizon A (2010) Determination of metallothionein in biological fluids using enzyme-linked immunoassay with commercial antibody. Acta Biochim Pol 57: 99-104.
  • Moffatt P, Seguin C (1998) Expression of the gene encoding metallothionein-3 in organs of the reproductive system. DNA Cell Biol 17: 501-510.
  • Oakley BR, Kirsch DR, Morris NR (1980) A Simplified Ultrasensitive Silver Stain for Detecting Proteins in Polyacrylamide Gels. Analytical Biochemistry 105: 361-363.
  • Pedersen MO, Larsen A, Stoltenberg M, Penkowa M (2009) The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64.
  • Pedersen MO, Hansen PB, Nielsen SL, Penkowa M (2010) Metallothionein-I plus II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas. Leuk Lymphoma 51: 314-328.
  • Penkowa M, Srensen BL, Nielsen SL, Hansen PB (2009) Metallothionein as a useful marker in Hodgkin lymphoma subclassification. Leuk Lymphoma 50: 200-210.
  • Petrlova J, Potesil D, Mikelova R et al. (2006) Attomole voltammetric determination of metallothionein. Electrochim Acta 51: 5112-5119.
  • Quaife CJ, Findley SD, Erickson JC et al. (1994) Induction of a New Metallothionein Isoform (Mt-Iv) Occurs During Differentiation of Stratified Squamous Epithelia. Biochemistry 33: 7250-7259.
  • Raspor B (2001) Elucidation of the mechanism of the Brdicka reaction. Journal of Electroanalytical Chemistry 503: 159-162.
  • Safi F, Kohler I, Rottinger E, Beger HG (1991) The value of the tumor-marker CA 15-3 in diagnosing and monitoring breast-cancer - a comparative study with carcinoembryonic antigen. Cancer 68: 574-582.
  • Sawyers CL (2008) The cancer biomarker problem. Nature 452: 548-552.
  • Shi YH, Amin K, Sato BG et al. (2010) The metal-responsive transcription factor-1 protein is elevated in human tumors. Cancer Biol Ther 9: 469-476.
  • Simpkins CO (2000) Metallothionein in human disease. Cell Mol Biol 46: 465-488.
  • Singh VK, Hanson J (2006) Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal. Pediatr Allergy Immunol 17: 291-296.
  • Szelachowska J, Dziegiel P, Jelen-Krzeszewska J et al (2008) Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851.
  • Szelachowska J, Dziegiel P, Jelen-Krzeszewska J et al. (2009) Correlation of Metallothionein Expression with Clinical Progression of Cancer in the Oral Cavity. Anticancer Res 29: 589-595.
  • Takeda A, Tamano H, Enomoto S, Oku N (2001) Zinc-65 imaging of rat brain tumors. Cancer Res 61: 5065-5069.
  • Telang U, Braeau DA, Morris ME (2009) Comparison of the Effects of Phenethyl Isothiocyanate and Sulforaphane on Gene Expression in Breast Cancer and Normal Mammary Epithelial Cells. Exp Biol Med 234: 287-295.
  • Vajtr D, Fabrik I, Adam V et al (2008) Metallothionein as a Marker of Spinocellular Carcinoma. Tumor Biol 29: 60-60.
  • Vyzkumny ustav pletarsky a.s, Brno Kizek R, Adam V (2009) Zpusob identifikace biologicky významných skutečností a zařízení k provádění tohoto způsobu (PV 2007-568). Vestnik uradu prumysloveho vlastnictvi 9: 2.
  • Wei H, Desouki MM, Lin S et al (2008) Differential expression of metallothioneins (MTs) 1 2 and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 7: 7.
  • Yang MY, Kroft SH, Chitambar CR (2007) Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1 metallothionein-2A and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 6: 633-643.
  • Yap XL, Tan HY, Huang JX et al (2009) Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 217: 563-570.
  • Yasuno T, Matsumura T, Shikata T et al (1999) Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line. Anticancer Res 19: 4049-4057.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv57p561kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.